REVIVA PHARMACEUTICALS HOLDINGS, INC.— Sankey Diagram
Quarterly mode · period ending 2020-11-30 · SEC EDGAR
ComparingFY2020 (Q4) vs FY2019 (Q4)
Revenue
$4K
↓-98.8% -$320Kvs FY2019 (Q4)
Gross Profit
$4K
↓-98.8% -$320Kvs FY2019 (Q4)
Operating Income
$4K
↓-98.8% -$320Kvs FY2019 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2020 (Q4) | FY2019 (Q4) |
|---|---|---|
| Revenue | $4K | $324K |
| COGS | $0 | $0 |
| Gross Profit | $4K | $324K |
| R&D | $0 | $0 |
| SG&A | $0 | $0 |
| D&A | $0 | $0 |
| Other OpEx | $0 | $0 |
| Operating Income | $4K | $324K |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $4K | $324K |
| Tax | $4K | $187K |
| Net Income | $0 | $137K |
QuarterCharts · SEC EDGAR data · RVPH · Comparing FY2020 (Q4) vs FY2019 (Q4)